About: http://webisa.webdatacommons.org/422249572

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	(5) Submission of an amendment to a supplement other than an efficacy or manufacturing supplement will not extend the initial review cycle.
http://www.w3.org/ns/prov#wasQuotedFrom	fda.gov